Skip to main content
SpringerLink
Log in

Natural Products and Supplements for Geriatric Depression and Cognitive Disorders: An Evaluation of the Research

  • Geriatric Disorders (W McDonald, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Numerous geriatric patients are using Complementary and Alternative Medicine (CAM) for late-life mood and cognitive disorders. Natural products and supplements are a common CAM intervention which have risks and benefits of which patients should be appropriately advised. The data for omega-3 fatty acids, ginkgo biloba, SAMe, St John’s wort, B vitamins and vitamin D, huperzine, caprylidene, and coconut oil will be evaluated. Since the evidence basis for natural products and supplements is limited, especially for the geriatric population, studies involving the general adult population are included to infer effects in the aging population. Despite the data available, more rigorous studies with larger sample sizes over longer periods of time are still needed. Regardless of a physician’s preference to recommend various natural supplements and products, a physician could protect their patients by having an understanding of the side effects and indications for various natural products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lavretsky H et al. Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders. Aging Health. 2009;5(1):61–78.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Lange H et al. Folate therapy in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673–81.

    Article  CAS  PubMed  Google Scholar 

  3. Mozaffari-Khosravi H. The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency. J Clin Psychopharmacol. 2012;33(3):378–84.

    Article  Google Scholar 

  4. Michaelsson K et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841–8.

    Article  CAS  PubMed  Google Scholar 

  5. NCCAM-NIH Website. What is Complementary and Alternative Medicine? http://nccam.nih.gov/health/whatiscam/. (National Center for Complementary and Alternative Medicine - National Institutes of Health, 2010).

  6. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Rep. 2007;2008:1–23.

    Google Scholar 

  7. US Food and Drug Administration. Orphan Drug Act (21 U.S.C. 360ee (b) (3)). Retrieved April 20, 2014, from http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/medicalfoods/default.htm (1988).

  8. Bertrand PC, O’Kusky JR, Innis SM. Maternal dietary (n-3) fatty acid deficiency alters neurogenesis in the embryonic rat brain. J Nutr. 2006;136(6):1570–5.

    CAS  Google Scholar 

  9. Birch E et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174–81.

    Article  CAS  PubMed  Google Scholar 

  10. Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351:1213.

    Article  CAS  PubMed  Google Scholar 

  11. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamaki H. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry. 2001;58:512–3.

    Article  CAS  PubMed  Google Scholar 

  12. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord. 2004;82:447–52.

    PubMed  Google Scholar 

  13. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91:757–70.

    Article  CAS  PubMed  Google Scholar 

  14. Sublette ME, Steven PE, Gleant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72:1577–84. Summary of dosing and proportion of omega-3 fatty acids and depression in general adult population.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Rondanelli M, Giacosa A, Opizzi A, et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutr Health Aging. 2011;15:37–44.

    Article  CAS  PubMed  Google Scholar 

  16. Giltay E, Geleijinse JM, Dromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr. 2011;94:1442–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407–12.

    Article  CAS  PubMed  Google Scholar 

  18. Sarris J, Dischoulon D, Schweitzer I. Omega-3 for bipolar disorder : meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81–6. Summary of omega-3 fatty acids and bipolar disorder in general adult population.

    Article  CAS  PubMed  Google Scholar 

  19. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol. 2009;5:140–52.

    Article  CAS  PubMed  Google Scholar 

  20. Schaefer EJ et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch Neurol. 2006;63(11):1545–50.

    Article  PubMed  Google Scholar 

  21. Barberger-Gateau P et al. Dietary patterns and risk of dementia. Neurology. 2007;69:1921–30.

    Article  CAS  PubMed  Google Scholar 

  22. Mazereeuw G, et al. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol. Aging. 2012;1482.e17–1482.e29. Omega-3 fatty acids can be helpful in mild cognitive impairment but no AD or normal cognition.

  23. Sydenham E, et al. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012. Summary of 3 well –designed studies showing no support for omega-3 fatty acids preventing the development of AD

  24. Trofimiuk E, Walesiuk A, Braszko JJ. St. John’s wort (Hypericum perforatum) diminishes cognitive impairment caused by chronic restraint stress in rats. Pharmacol Res. 2004;51:239–46.

    Article  Google Scholar 

  25. Hammerness P et al. St. John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44(4):271–82.

    Article  CAS  PubMed  Google Scholar 

  26. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst. Rev. 2008;CD000448.

  27. Kasper S, Gastpar M, Moller HJ, Muller WE, Volz HP, Dienel A, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204–13.

    Article  PubMed  Google Scholar 

  28. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. J Am Med Assoc. 2002;287:1807–14.

    Article  Google Scholar 

  29. Shelton RC. St John's wort (Hypericum perforatum) in major depression. J Clin Psychiatry. 2009;70 Suppl 5:23–7.

    Article  PubMed  Google Scholar 

  30. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978–86.

    Article  CAS  PubMed  Google Scholar 

  31. Sarris J, Fava M, Schweitzer I, Mischoulon D. St. John’s wort (hypericum perforatum) verses sertraline and placebo in major depressive disorder : continuation data from a 26-week RCT. Pharmacopsychiatry. 2012;45(7):275–8.

    Article  CAS  PubMed  Google Scholar 

  32. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung. 1999;49:289–96.

    CAS  PubMed  Google Scholar 

  33. Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St. John’s wort extract L160 for the treatment of depression with atypical features-a double-blind randomized, and placebo-controlled trial. J Psychiatr Res. 2001;44:760–7.

    Article  Google Scholar 

  34. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69:1777–98.

    Article  CAS  PubMed  Google Scholar 

  35. Kashiwaya Y et al. D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. PNAS. 2000;97(5):5440–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Izzo AA et al. Interactions between herbal medicines and prescribed drugs an updated systematic reviews. Drugs. 2009;69(13):1888–98.

    Article  Google Scholar 

  37. Thaipisuttikul P, Galvin J. Use of medical foods and nutritional approaches in treatment of Alzheimer’s disease. Clin Pract. 2012;9(2):199–209. Review of 3 popular medical foods for dementia.

    Article  CAS  Google Scholar 

  38. Varteresian T et al. The use of natural products and supplements in late-life mood and cognitive disorders. FOCUS. 2013;11(1):15–21. Previous review of Natural products by current authors.

    Article  Google Scholar 

  39. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S–61.

    CAS  PubMed  Google Scholar 

  40. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:18–22.

    Article  CAS  PubMed  Google Scholar 

  41. Paul RT, McDonnell AP, Kelly CB. Folic acid: neurochemistry, metabolism and relationship to depression. Hum Psychopharmacol. 2004;19:477–88.

    Article  CAS  PubMed  Google Scholar 

  42. Bottiglieri T et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7–14.

    Article  CAS  PubMed  Google Scholar 

  44. Alpert JE et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder. J Clin Psychopharmacol. 2004;24(6):661–4.

    Article  CAS  PubMed  Google Scholar 

  45. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167:942–8.

    Article  PubMed  Google Scholar 

  46. DiRocco A et al. S-adenosyl-methionine improves mdepression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord. 2000;15(6):1225–9.

    Article  CAS  Google Scholar 

  47. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S–61.

    CAS  PubMed  Google Scholar 

  48. Carney MW, Chary TK, Bottiglieri T, Reynolds EH, Toone BK. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry J Ment Sci. 1987;150:724–5.

    Article  CAS  Google Scholar 

  49. Chitiva H, Audivert F, Alvarez C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine. J Nerv Ment Dis. 2012;200:99–101.

    Article  PubMed  Google Scholar 

  50. Fontanari D, Palma C, Giorgetti G, Violante F, Voltolina M. Effects of S-adenosyl-L-methionin on cognitive and vigilance functions in the elderly. Curr Ther Res. 1994;55:682–8.

    Article  Google Scholar 

  51. Levkovitz Y, Alpert J, Brintz C, Mischoulon D, Papakostas G. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2011;136:1174–8. RCT showing SAMe augmentation of SSRI benefiting cognitive symptoms in depression.

  52. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Kohler S, Funk P, Kieser M. Influence of 7-day treatment with ginkgo biloba special extract Egb 761 on bleeding time and coagulation : a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303–9.

    Article  PubMed  Google Scholar 

  54. Vellas B et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11:851–9. Well designed study showing lack of preventatie effect of Ginkgo Biloba on the development of dementia.

    Article  CAS  PubMed  Google Scholar 

  55. Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA. 2009; 2663–2670.

  56. Amieva H et al. Ginkgo biloba extract and long-term cognitive decline : a 20-year follow-up population based study. PLoS ONE. 2013;8(1):e52755.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of ginkgo biloba extract EGb 761 i n Alzheimer’s Disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012;45:41–6. RCT showing ginkgo biloba being effective for multiple types of dementia.

    Article  CAS  PubMed  Google Scholar 

  58. Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157:295–300.

    Article  PubMed  Google Scholar 

  59. Sierpina VS et al. Ginkgo biloba. Am Fam Physician. 2003;68(5):923–6.

    PubMed  Google Scholar 

  60. Zhi-Qiang X, Xiao-Min L, Juan W, Yuan-Feng Z, Chun-Xia Z, Xiao-Jiang J. Treatment with huperzine A improves cognition in vascular dementia patients. Cell Biochem Biophys. 2012;62:55–8. Study from China showing Huperzine being effective for vascular dementia.

    Article  Google Scholar 

  61. Rafii MS et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76:1389–94. Study from U.S. showing only high dosage huperzine being effective for Alzheimer’s disease.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  62. Beydoun M, Shroff M, Beydoun H, Zonderman A. Serum folate, vitamin B-12, and homocysteine and their associations with depressive symptoms among US adults. Psychosom Med. 2010;72:862–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Forti P, Rietti E, Pisacane N, Olivelli V, Dalmonte E, Mecocci P, et al. Blood homocysteine and risk of depression in the elderly. Arch Gerontol Geriatr. 2010;51:21–5.

    Article  CAS  PubMed  Google Scholar 

  64. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan A, Breteler M. Vitamin B12, folate, and homocysteine in depression : the Rotterdam Study. Am J Psychiatr. 2002;159:2099–101.

    Article  PubMed  Google Scholar 

  65. Walker J et al. Mental health literacy, folic acid and vitamin B12 and physical activity for the prevention of depression in older adults : randomized controlled trial. Br J Psychiatry. 2010;197:45–54.

    Article  PubMed  Google Scholar 

  66. Almeida O, Marsh K, Alfonso H, Flicker L, Davis T, Hankey G. B-vitamins reduce the long-term risk of depression after stroke : the VITATOPS-DEP trial. Ann Neurol. 2010;68:503–10.

    Article  CAS  PubMed  Google Scholar 

  67. Papakostas GI et al. L-methyfolate as adjunctive therapy for SSRI-resistant major depression : results of two randomized, double blind, paralleel-sequential trials. Am J Psychiatry. 2012;169(12):1267–74. Well –designed study showing benefit of l-methyfolate augmentation of antidepressant in general adult population.

    Article  PubMed  Google Scholar 

  68. Resler G, Lavie R, Campos J, Mata S, Urbina M, Garcia A, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12 and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15:145–52.

    Article  CAS  PubMed  Google Scholar 

  69. Abou-Saleh M, Coppen A. Folic acid and the treatment of depression. J Psychosom Res. 2006;61:285–7.

    Article  PubMed  Google Scholar 

  70. Seeley WW, Miller BL. Chapter 371. Dementia. In: Longo DL, Fauci, AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine, 18e. Retrieved September 17, 2012 from http://www.accessmedicine.com/content.aspx?aID=9146233 (2012).

  71. Tangney CC et al. Vitamin B12, cognition, and brain MRI measures. Neurology. 2011;77:1276–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Aisen P, Schneider L, Sano M, Fiaz-Arrastia R, van-Dyck C, Weiner M, et al. High dose B vitamin supplementation and cognitive decline in Alzheimer Disease. JAMA. 2008;300:1774–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Kwok T et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30:297–302.

    Article  CAS  PubMed  Google Scholar 

  74. Walker J et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms-the Beyond Aging Project : a randomized controlled trial. Am J Clin Nutr. 2012;95:194–203. In older adults with depressive symptoms but without dementia showed vitamin B12 supplementation can improve attention and delayed recall.

    Article  PubMed  Google Scholar 

  75. Mursu J, Robien K, Harnack L, Park K, Jacobs D. Dietary supplements and mortality rate in older women. Arch Intern Med. 2011;171:1625–33. Epidemioliogical study showing some risk of supplements in increasing mortality in older women.

    Article  CAS  PubMed  Google Scholar 

  76. Tariq MM et al. Vitamin D : a potential role in reducing suicide risk. Int J Adolesc Med Health. 2011;23(3):157–65. Correlation between vitamin D deficiency and increased risk for suicide in general adult popultation.

    Article  PubMed  Google Scholar 

  77. Dumville JC et al. Can vitamin D supplementation prevent winter-time blues ? a randomized trial among older women. J Nutr Health Aging. 2006;10(2):151–3.

    CAS  PubMed  Google Scholar 

  78. Chan A, et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open label pilot study with a 16-month caregiver extension. Am J Alzheimers Dis Other Dement. 2009;571–585.

  79. Bertone-Johnson ER et al. Vitamin D supplementation and depression in the Women’s Health Initiative Calcium and Vitamin D Trial. Am J Epidemiol. 2011;176(1):1–13. Low dosage vitamin D supplementation did not improve depression in older females suffering from depression.

    Article  Google Scholar 

  80. Jorde R et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects : randomized double blind trial. J Intern Med. 2008;264:599–609.

    Article  CAS  PubMed  Google Scholar 

  81. Henderson ST et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease : a randomized, double-blind placebo-controlled multicenter trial. Nutr Metab. 2009;6:31.

    Article  Google Scholar 

  82. Doty L. Coconut oil for Alzheimer’s disease. Clin Pract. 2012;1(2):12–7. Review demonstrating how coconut oil is not effective for Alzheimer’s disease.

    Google Scholar 

  83. Stoll AL, Damico KE, Daly BP, Severus WE, Marangell LB. Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. World Rev Nutr Diet. 2001;88:58–67.

    Article  CAS  PubMed  Google Scholar 

  84. Michaelsson K, Baron J, Snellman G, Gedborg R, Byberg L, Sundstrom J, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841–48.

  85. Qureshi NA et al. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat. 2013;9:639–58. Extensive review of CAM for adult mood disorders.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Kaustubh JG, Faubion MD. Mania and psychosis associated with St. John’s wort and ginseng. Psychiatry. 2005;56–61.

  87. Borrelli F, Izzo AA. Herb-drug interactions with St. John’s wort (Hypericum perforatum) an update on clinical observations. AAPS J. 2009;11:710–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Taya Varteresian declares no conflict of interest.

Helen Lavretsky declares that this work was supported by the NIH grants MH077650, MH86481 and AT003480, and grants from the Forest Research Institute, and Alzheimer’s Research and Prevention Foundation to Dr. Lavretsky.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, C9-948A, Los Angeles, CA, 90095, USA

    Helen Lavretsky

  2. VA Long Beach Health Care System, 5901 East 7th Street, Long Beach, CA, 90822, USA

    Taya Varteresian

  3. University of California Irvine, Irvine, CA, 92697, USA

    Taya Varteresian

Authors
  1. Taya Varteresian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen Lavretsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen Lavretsky.

Additional information

This article is part of the Topical Collection on Geriatric Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varteresian, T., Lavretsky, H. Natural Products and Supplements for Geriatric Depression and Cognitive Disorders: An Evaluation of the Research. Curr Psychiatry Rep 16, 456 (2014). https://doi.org/10.1007/s11920-014-0456-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-014-0456-x

Keywords

Search

Navigation